Industry · Pharma

Bringing Chinese medicines to European and American patients.

NMPA/CDE data → EU CTA / FDA IND planning → EU and US marketing-application strategy.

Innovative products, generics and biosimilars, with marketing authorisation strategy, manufacturing compliance and lifecycle management designed for the European system.

AuthoritiesEMA · national agencies
ManufacturingEU GMP readiness
Product typesNCE · Generic · Biosimilar
Overview

A harmonised framework on one side, a single federal regulator on the other.

EMA coordinates the centralised procedure, while national competent authorities handle national, decentralised and mutual-recognition routes. Biotechnology-derived biosimilars require the centralised route. National access and distribution requirements also shape planning.

Kaiveo Medical helps Chinese pharmaceutical companies assess dossier readiness, manufacturing compliance, clinical evidence and market sequencing through founder-led coordination. For drug-led combination products, the medicines pathway leads, with device-component requirements assessed as applicable. Import, testing and statutory-role needs are assessed with your responsible functions.

Challenges we solve

Procedure choice & market sequencing

Centralised versus decentralised or national, and in which order to approach member states.

Dossier readiness

CTD gap closure, Module 3 depth, bioequivalence and clinical-overview quality that European assessors expect.

EU GMP for Chinese sites

Inspection readiness for API and finished-product sites, data-integrity programmes and CDMO oversight.

Import, testing & QP requirements

Assessment of import, testing and QP requirements, with appropriately qualified providers identified as needed; appointments agreed separately.

Biosimilar strategy

Comparability exercise design, reference-product sourcing and European biosimilar guideline alignment.

Lifecycle & safety requirements

Variations, renewals and regulatory intelligence within scope; safety-system and QPPV needs assessed with your responsible functions.

How we support pharma clients

The same product, two regulators

Approval in one market does not carry over to the other. The relevance and sufficiency of existing evidence must be assessed for each intended route.

In Europe

  • EMA centralised or NCA national, decentralised / MRP routes
  • EU GMP readiness and assessment of QP batch-release needs
  • Assessment of safety and trial legal-representation requirements
  • Importation and supply-chain requirements assessment
  • Orphan designation, PRIME eligibility and paediatric plans
  • Early HTA and payer evidence questions

In the United States

  • IND for clinical trials; NDA 505(b)(1)/(2) or ANDA for generics
  • BLA 351(a) for biologics or 351(k) for biosimilars
  • cGMP under 21 CFR Parts 210 and 211, and FDA inspection
  • Fast Track, Breakthrough Therapy and Priority Review
  • Assessment of US payer evidence questions

A typical pharma pathway

Feasibility & procedure selection

Product, data and manufacturing assessed; European procedure and market sequence recommended.

Dossier & site preparation

CTD gaps closed while manufacturing sites are brought to EU GMP inspection readiness in parallel.

Submission & assessment

Agreed submission coordination and support for questions and inspections; regulatory decisions remain with the authorities.

Launch & lifecycle

Agreed lifecycle planning and coordination of launch requirements with your appointed responsible functions and providers.

Frequently asked

Is the centralised procedure mandatory for our product?
It is mandatory for specified categories, including biotechnology-derived biosimilars, and optional for some others. We assess legal eligibility and the fit of the EMA centralised or NCA-led routes for your product.
How long does EU GMP readiness typically take for a Chinese site?
It depends on the site, product, existing controls and remediation scope. A gap assessment supports an individual plan; scope and schedule are agreed per engagement.
Can Kaiveo Medical help with pricing and reimbursement?
We can assess early HTA and payer evidence questions within development planning and help identify an appropriate specialist provider. Pricing, negotiation or reimbursement submission services require separately confirmed arrangements.
Pharma

Let's map your product's route to European approval.

A confidential conversation about your pipeline is the fastest way to start.

We aim to reply within two working days. Language support is agreed for each engagement.